Wealth Enhancement Advisory Services’s GSK GSK Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.06M	Buy	114,888 +12,789	+13%	+$676K	0.01%	897
2026 Q1	$5.56M	Sell	102,099 -26,418	-21%	-$1.43M	0.01%	853
2025 Q4	$6.51M	Sell	128,517 -24,912	-16%	-$1.16M	0.01%	890
2025 Q3	$6.67M	Sell	153,429 -16,240	-10%	-$634K	0.01%	822
2025 Q2	$6.48M	Sell	169,669 -8,841	-5%	-$338K	0.01%	793
2025 Q1	$6.92M	Buy	178,510 +3,822	+2%	+$140K	0.01%	717
2024 Q4	$5.91M	Buy	174,688 +13,039	+8%	+$469K	0.01%	741
2024 Q3	$6.61M	Sell	161,649 -4,606	-3%	-$188K	0.01%	642
2024 Q2	$6.4M	Buy	166,255 +8,989	+6%	+$378K	0.02%	621
2024 Q1	$6.74M	Buy	157,266 +4,082	+3%	+$168K	0.02%	592
2023 Q4	$5.68M	Buy	153,184 +78,527	+105%	+$2.82M	0.02%	577
2023 Q3	$2.71M	Buy	+74,657	New	+$2.65M	0.01%	757

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wealth Enhancement Advisory Services's GSK Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its GSK (GSK) stake by 13% in Q2 2026, buying an estimated $676K and bringing the position to 114,888 shares worth $6.06M. The position accounts for 0.01% of the portfolio, ranked #897.

Wealth Enhancement Advisory Services first reported a position in GSK in Q3 2023 and has held it in 12 quarters since. The position peaked at $6.92M in Q1 2025. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Wealth Enhancement Advisory Services held 114,888 shares of GSK worth $6.06M as of Q2 2026.
Wealth Enhancement Advisory Services bought 12,789 GSK shares in Q2 2026, an estimated $676K.
GSK made up 0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #897 holding.
Wealth Enhancement Advisory Services first reported a position in GSK in Q3 2023 and has held it in 12 quarters since.
Wealth Enhancement Advisory Services's GSK position peaked at $6.92M in Q1 2025.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.